Current & Past Research


The NIH sponsored RECOVER trial, an observational study to understand the long-term effects of COVID-19, launched at SHC-TV in Sept 2022. The study is led by Dr. Minjoung Go in the division of Hospital Medicine along with sub investigators, Dr. Kathleen Jia in the division of Hospital Medicine, Dr. Jake Scott in the division of Infectious Diseases, and Dr. Orlando Quintero also in the division of Infectious Diseases. The study involves 3 study visits in the first year and then once yearly visits thereafter for 3-4 years. Blood tests, urine, vital signs/assessments will be done, and participants will receive a survey every 3 months.


Medtronic Ellipsys Post Market Surveillance Study

  • The Medtronic Ellipsys Post Market Surveillance Study began recruiting patients at SHC Tri-Valley in November 2022. This study is led by Dr. Karthik Kasirajan of the Vascular Surgery department at SHC Tri-Valley. The purpose of this observational study is to evaluate the safety and effectiveness of the Ellipsys Vascular Access System in the creation of a native AV fistula via percutaneous access in dialysis patients.  

Karthik Kasirajan, MD


  • In May 2021, the first outpatient clinical trial, the Camostat trial, was launched at SHC Tri-Valley in partnership with Stanford University. The study evaluated the efficacy of camostat, a drug given to newly diagnosed COVID patients who did not need to be hospitalized. This study was part of the COVID-19 Outpatient Pragmatic Platform Study (COPPS) led by Dr. Manisha Desai and Dr. Julie Parsonet of the Division of  Infectious Diseases at Stanford University. SHC-VC served as a sub sitefor this study. At SHC Tri-Valley, efforts were led by infectious disease physicians, Dr. Jake Scott, who served as the site PI and Dr. Orlando Quintero, who was the sub-investigator in partnership with SCCR. The study is currently on hold until further notice.  

Jake Scott, MD

Orlando Quintero, MD 

TRACK COVID Public Health Surveillance Study 

From November 2020 to March 2021, SHC Tri-Valley has served as a site for the TRACK study. Led by Dr. Jenna Bollyky, this public health surveillance study collects monthly nasopharyngeal swabs, blood draws and online surveys from adults living in the Bay Area. The goal is to understand how many people are currently infected with COVID-19, how likely it is someone will become infected, and  the body’s immune response to the coronavirus and the duration of immunity. The study is funded by the Chan Zuckerberg initiative and is in partnership with UCSF. The study successfully enrolled 271 participants at SHC Tri-Valley for a total of 1329 visits. For more information, please visit


NIH Adaptable COVID Treatment Trials (ACTT)

 In response to the COVID pandemic, the first clinical trial launched at SHC-VC was the ACTT-1 trial. The trial was initially brought to Stanford University's main campus in Palo Alto by the Division of Hospital Medicine and principal investigators, Dr. Kari Nadeau and Dr. Neera Ahuja. SHC Tri-Valley served as a subsite to Stanford Palo Alto. As hospitalists based at SHC Tri-Valley, Dr. David Svec, Dr. Minjoung Go and Dr. Evelyn Ling served as the sub-investigators with support from the research team at the Stanford Center for Clinical Research (SCCR).

The NIH ACTT trial was one of the first large multi-site double blinded placebo controlled trials to evaluate treatments for hospitalized patients with COVID.  The first arm of the trial enrolled 1062 patients (2 at SHC Tri-Valley) and showed that remdesivir shortened time to recovery and led to the FDA approval. It has now become the standard of care treatment for hospitalized COVID patients. (see Dr. Ling was featured on NPR discussing the preliminary results ( 

Since the trial structure is adaptive, it has enabled other potential therapies to also be trialed in the study. The trial has completed two subsequent arms, evaluating the drugs, barcitinib and interferon. SHC Tri-Valley has enrolled 5 and 7 patients respectively in these arms. The fourth arm of the trial was completed in early 2021 evaluating the combination remdesivir + baricitinib and remdesivir and dexamethasone.

Publications in the NEJM 



Evelyn Ling, MD